Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;34(10):1726-1728.
doi: 10.1038/s41433-020-0853-9. Epub 2020 Apr 6.

Brolucizumab and immunogenicity

Ashish Sharma  1 , Nilesh Kumar  2 , Nikulaa Parachuri  2 , Rohini Sharma  3 , Francesco Bandello  4 , Baruch D Kuppermann  5 , Anat Loewenstein  6
Affiliations

Brolucizumab and immunogenicity

Ashish Sharma et al. Eye (Lond). 2020 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

AS: consultant: for Novartis, Allergan, Bayer and Intas. FB: consultant: Allergan, Bayer, Boehringer-Ingelheim, Fidia Sooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, Thrombogenics, Zeiss. BDK: clinical research: Alcon, Alimera, Allegro, Allergan, Apellis, Clearside, Genentech, GSK, Ionis, jCyte, Novartis, Regeneron, ThromboGenics; consultant: Alimera, Allegro, Allergan, Cell Care, Dose, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics, jCyte, Novartis, Ophthotech, Regeneron, Revana, Theravance Biopharma. AL reports other from Allergan, other from Novartis, other from Roche, other from Notal Vision, other from Forsightslabs, other from Beyeonics, other from Bayer Health Care. NK, NP, and RS: none

References

    1. Sharma A, Kumar N, Kuppermann BD, Bandello F. Brolucizimab-leading an era of structural revolution for long-term VEGF suppression. Eye (Lond) 2020;34:611–3. doi: 10.1038/s41433-019-0583-z. - DOI - PMC - PubMed
    1. Antonio Ligi. Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept. https://www.novartis.com/news/media-releases/novartis-receives-fda-appro.... Accessed Mar 2020.
    1. Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72–84. doi: 10.1016/j.ophtha.2019.04.017. - DOI - PubMed
    1. Clinical Updates: Beovu Update for ASRS Members. 2020. https://www.asrs.org/clinical/clinical-updates/960/Beovu-Update-for-ASRS....
    1. Kuriakose A, Chirmule N, Nair P. Immunogenicity of biotherapeutics: causes and association with posttranslational modifications. J Immunol Res. 2016;2016:1298473. doi: 10.1155/2016/1298473. - DOI - PMC - PubMed

Substances